\n\n Ulcerative Colitis Market <\/span><\/b>Report Scope<\/b><\/o:p><\/p>\n<\/td>\n<\/tr>\n\n\n Report Coverage<\/b><\/o:p><\/p>\n<\/td>\n\n Details<\/b><\/o:p><\/p>\n<\/td>\n<\/tr>\n\n\n Market size value in 2021<\/span><\/o:p><\/span><\/p>\n<\/td>\n\n US$ 6.92 Billion<\/span><\/o:p><\/span><\/p>\n<\/td>\n<\/tr>\n\n\n Market forecast in 2027<\/span><\/o:p><\/span><\/p>\n<\/td>\n\n US$ 9.71 Billion<\/span><\/o:p><\/span><\/p>\n<\/td>\n<\/tr>\n\n\n Growth Rate<\/span><\/o:p><\/span><\/p>\n<\/td>\n\n CAGR of 5.60% from 2022 to 2027<\/span><\/o:p><\/span><\/p>\n<\/td>\n<\/tr>\n\n\n Base year for estimation<\/span><\/o:p><\/span><\/p>\n<\/td>\n\n 2021<\/span><\/o:p><\/span><\/p>\n<\/td>\n<\/tr>\n\n\n Historical data<\/span><\/o:p><\/span><\/p>\n<\/td>\n\n 2016-2021<\/span><\/o:p><\/span><\/p>\n<\/td>\n<\/tr>\n\n\n Forecast period<\/span><\/o:p><\/span><\/p>\n<\/td>\n\n 2022-2027<\/span><\/o:p><\/span><\/p>\n<\/td>\n<\/tr>\n\n\n Report coverage<\/span><\/o:p><\/span><\/p>\n<\/td>\n\n Revenue forecast, company ranking, competitive landscape, growth factors, and trends<\/span><\/o:p><\/span><\/p>\n<\/td>\n<\/tr>\n\n\n Segments covered<\/span><\/o:p><\/span><\/p>\n<\/td>\n\n Type, Disease Type, Molecule Type, Drug Type, Route of Administration, Distribution Channel and Region<\/span><\/o:p><\/span><\/p>\n<\/td>\n<\/tr>\n\n\n Regional scope<\/span><\/o:p><\/span><\/p>\n<\/td>\n\n North America, Europe, Asia-Pacific, Latin America, Middle East and Africa<\/span><\/o:p><\/span><\/p>\n<\/td>\n<\/tr>\n\n\n Key companies profiled<\/span><\/o:p><\/span><\/p>\n<\/td>\n\n Abbott Laboratories, AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.<\/span><\/o:p><\/span><\/p>\n<\/td>\n<\/tr>\n\n\n Market Dynamics<\/span><\/o:p><\/span><\/p>\n<\/td>\n\n Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for forecast period,<\/span><\/o:p><\/span><\/p>\n<\/td>\n<\/tr>\n\n\n Customization preview<\/span><\/o:p><\/span><\/p>\n<\/td>\n\n If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.<\/span><\/o:p><\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nReport Segmentation: <\/b><\/p>\n The report has been segmented the market into following categories:\n<\/p>\n Breakup by Type:<\/b><\/p>\n \u2022 <\/span>Mild UC<\/p>\n\u2022 <\/span>Moderate UC<\/p>\n\u2022 <\/span>Severe UC\n<\/p>\nBreakup by Disease Type:<\/b><\/p>\n \u2022 <\/span>Ulcerative Proctitis<\/p>\n\u2022 <\/span>Proctosigmoiditis<\/p>\n\u2022 <\/span>Left-sided Colitis<\/p>\n\u2022 <\/span>Pancolitis or Universal Colitis<\/p>\n\u2022 <\/span>Fulminant Colitis\n<\/p>\nBreakup by Molecule Type:<\/b><\/p>\n \u2022 <\/span>Small Molecules<\/p>\n\u2022 <\/span>Biologics\n<\/p>\nBreakup by Drug Type:<\/b><\/p>\n \u2022 <\/span>Anti-Inflammatory Drugs<\/p>\n\u2022 <\/span>Anti-TNF Biologics<\/p>\n\u2022 <\/span>Immunosuppressant<\/p>\n\u2022 <\/span>Calcineurin Inhibitors<\/p>\n\u2022 <\/span>Others\n<\/p>\nBreakup by Route of Administration:<\/b><\/p>\n \u2022 <\/span>Oral<\/p>\n\u2022 <\/span>Injectable\n<\/p>\nBreakup by Distribution Channel:<\/b><\/p>\n \u2022 <\/span>Hospital Pharmacies<\/p>\n\u2022 <\/span>Retail Pharmacies<\/p>\n\u2022 <\/span>Drug Store<\/p>\n\u2022 <\/span>Others\n<\/p>\nBy Geography: \n<\/b><\/div>\n\u2022 <\/span>North America<\/b><\/p>\no <\/span>United States<\/p>\no <\/span>Canada\n<\/p>\n\u2022 <\/span>Asia-Pacific<\/b><\/p>\no <\/span>China<\/p>\no <\/span>Japan<\/p>\no <\/span>India<\/p>\no <\/span>South Korea<\/p>\no <\/span>Australia<\/p>\no <\/span>Indonesia<\/p>\no <\/span>Others\n<\/p>\n\u2022 <\/span>Europe<\/b><\/p>\no <\/span>Germany<\/p>\no <\/span>France<\/p>\no <\/span>United Kingdom<\/p>\no <\/span>Italy<\/p>\no <\/span>Spain<\/p>\no <\/span>Russia<\/p>\no <\/span>Others\n<\/p>\n\u2022 <\/span>Latin America<\/b><\/p>\no <\/span>Brazil<\/p>\no <\/span>Mexico<\/p>\no <\/span>Others\n<\/p>\n\u2022 <\/span>Middle East and Africa \n<\/b><\/div>\n | | | | | | | | | | | | | | | | | | | | | | | | | | |